Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.

@article{Marchi2016EndocrineTR,
  title={Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.},
  author={Tommaso De Marchi and John A. Foekens and Arzu Umar and John W. M. Martens},
  journal={Drug discovery today},
  year={2016},
  volume={21 7},
  pages={1181-8}
}
Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…